A new nationwide survey of cancer patients, caregivers and doctors details the negative effects insurance utilization management policies in private insurance have had on patient care and what those policies could mean should proposed changes to Medicare’s Part D’s “six protected classes” prescription drug coverage policy go into effect.
Cancer patients, survivors and caregivers will tune into the president’s State of the Union address to see if the president will commit to strengthen the nation's health care system, support life-saving medical research and improve quality of life for patients.
On Friday the American Cancer Society Cancer Action Network (ACS CAN) along with nearly 60 other patient advocacy organizations sent a letter to the Department of Health and Human Services (HHS) about how proposed changes to Medicare Part D’s six protected classes could hurt cancer patients’ time
Today the American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Department Health and Human Services (HHS) detailing ways in which proposed changes to Medicare Part D’s six protected classes could jeopardize cancer patients’ timely access to drug therapies.
The American Cancer Society Cancer Action Network (ACS CAN) is launching a new print and digital ad campaign today emphasizing the dangerous impact that proposed changes to Medicare Part D’s six protected classes could have on patients’ access to affordable drug therapies.
The Department of Health and Human Services announced proposed changes to the Medicare Part C and D regulations today that if finalized could dramatically impact access to affordable medication and quality care for cancer patients on the program. The administration is proposing to alter rules around Medicare Part D’s “Six Protected Classes.” The proposals could have cost, care and safety implications.
On Friday, October 26, ACS CAN will host its annual policy forum in Oregon. This year's event focuses on the pressing issues surrounding the cost of breast cancer across different types of insurance.
The Center for Medicare and Medicaid Services (CMS) issued guidance last night giving Medicare Advantage plans the option of applying step therapy for physician-administered and other Part B drugs, effective January 1, 2019.
Today the American Cancer Society Cancer Action Network submitted comments to the Department of Health and Human Services (HHS) regarding proposals to reduce prescription drug costs outlined in the administration’s Request for Information (RFI) regarding its Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (blueprint).
Proposals expected to be announced as part of the administration's American Patients First plan, include various changes to Medicare’s prescription drug program, such as protecting beneficiaries from catastrophic costs through an out-of-pocket maximum, and requiring plans to share a minimum portion of drug rebates with patients.